)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Ypsomed Holding (YPSN) investor relations material
Ypsomed Holding H1 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 25/26 earnings summary12 Nov, 2025
Executive summary
Completed transformation to a pure-play self-injection specialist, divesting non-core businesses including Diabetes Care, Pen Needles, and Ypsotec between 2022 and 2025.
Achieved strong first-half results, with consolidated sales of CHF 362.7 million in H1 2025/26, up 12% year-over-year, and robust operational execution in Delivery Systems.
Launched innovative, recyclable device platforms (YpsoDot, YpsoFlow, YpsoLoop) and received FDA approval for digital devices in clinical trials.
Expanded global manufacturing footprint with new facilities in Germany, China, and the U.S., aiming for 1 billion device capacity by the end of the decade.
Focused on innovation, operational excellence, and strong financials, positioning for significant end-market growth.
Financial highlights
Group sales reached CHF 363 million in H1 2025/26, with Delivery Systems contributing CHF 267 million, up 21% year-over-year.
EBIT for H1 was CHF 151.7 million, including a CHF 74.6 million book profit from the Diabetes Care sale; core Delivery Systems EBIT was CHF 87 million (32.4% margin).
Operating cash flow exceeded CHF 140 million for the core business; free cash flow was around CHF 288 million, boosted by divestitures.
ROCE in the core business was approximately 21%; equity ratio improved to 66.8%, and net debt/EBITDA was 0.3.
Net profit for H1 2025/26 was CHF 139.1 million, with EPS rising to CHF 10.19.
Outlook and guidance
Full-year guidance confirmed: ~20% sales growth and EBIT between CHF 190–210 million for Delivery Systems.
Midterm ambition: double sales to CHF 0.9–1.2 billion and reach CHF 280–340 million EBIT by 2029/30, maintaining EBIT margin above 30% and ROCE around 20%.
Growth in auto-injectors expected to outpace pens; contract manufacturing phase-out will temporarily impact growth in 2026–2027.
How is the Diabetes Care earn-out estimate derived?
YpsoLoop/SmartPilot: expected market adoption?
US plant: quantify tariff savings and supply stability?
How will YpsoFit address EBIT margin dilution?
What is the contracted capacity for 2030?
What drives flat pen sales vs auto-injector growth?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Ypsomed Holding earnings date
H2 25/2620 May, 2026
Next Ypsomed Holding earnings date
H2 25/2620 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Ypsomed Holding AG is a Switzerland-based medical device company that specializes in the design, development, and manufacture of injection and infusion systems for self-medication. It provides a wide range of products, including autoinjectors, dual chamber pens, and pen injectors, catering to various medical conditions such as diabetes, infertility, and growth disorders. Ypsomed also offers comprehensive services from design and development to manufacturing and assembly, supporting pharmaceutical and biotechnology companies throughout the product lifecycle. Ypsomed's headquarters are located in Burgdorf, Switzerland, and its shares are listed on the SWX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage